SCHEMBL333131

SCHEMBL333131

O=C(CC(=O)OCc1ccccc1)Nc1cccc(C(F)(F)F)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.62
HTT P42858 4/20 0.62
MEN1 O00255 6/20 0.61
KMT2A Q03164 6/20 0.61
MAPT P10636 5/20 0.61
XBP1 P17861 2/20 0.60
GAA P10253 2/20 0.60
NPSR1 Q6W5P4 1/20 0.60
MGLL Q99685 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.57
ALOX12 P18054 2/20 0.57
KDM4E B2RXH2 1/20 0.57
RAB9A P51151 1/20 0.57
RXFP1 Q9HBX9 2/20 0.57
L3MBTL1 Q9Y468 2/20 0.56
NTRK1 P04629 1/20 0.55
NTRK2 Q16620 1/20 0.55
PPIA P62937 1/20 0.54
HPGD P15428 2/20 0.52
HDAC3 O15379 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19688778 0.86 MGLL (0.76) ALDH1A1HTTMEN1KMT2AMAPT
SCHEMBL964881 0.84 MEN1 (0.78) ALDH1A1HTTMEN1KMT2AMAPT
SCHEMBL20029049 0.84 MGLL (0.59) ALDH1A1HTTMEN1KMT2AMAPT
SCHEMBL333191 0.83 SMN1; SMN2 (0.65) ALDH1A1HTTMEN1KMT2AMAPT
SCHEMBL5027273 0.83 NLRP3 (0.53) ALDH1A1HTTMAPTGAAMGLL
SCHEMBL5142569 0.82 MAPT (0.77) ALDH1A1HTTMEN1KMT2AMAPT
SCHEMBL29550745 0.81 KMT2A (0.84) ALDH1A1HTTMEN1KMT2AMAPT
SCHEMBL1603669 0.81 SMN1; SMN2 (0.74) ALDH1A1HTTMEN1KMT2AMAPT
SCHEMBL8347078 0.81 SMN1; SMN2 (0.66) ALDH1A1HTTMEN1KMT2AMAPT
SCHEMBL5142590 0.81 MAPT (0.77) ALDH1A1HTTMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1620391-B1 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL MYERS SQUIBB CO (US) 2014-01-15 EP disclosed
US-8097629-B2 Dihydropyridinone derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-01-17 US disclosed
US-8097629-B2 Dihydropyridinone derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-01-17 US disclosed
US-8097629-B2 Dihydropyridinone derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-01-17 US disclosed
EP-1720857-B1 DIHYDROPYRIDINONE DERIVATIVES BAYER SCHERING PHARMA AG (DE) 2011-07-13 EP disclosed
US-7696205-B2 Cyclic derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2010-04-13 US disclosed
US-20080108678-A1 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2008-05-08 US disclosed
US-20080045541-A1 Dihydropyridinone Derivatives BAYER-HEALTHCARE AG (DE) 2008-02-21 US disclosed
US-20080045541-A1 Dihydropyridinone Derivatives BAYER-HEALTHCARE AG (DE) 2008-02-21 US disclosed
US-20080045541-A1 Dihydropyridinone Derivatives BAYER-HEALTHCARE AG (DE) 2008-02-21 US disclosed
US-7291615-B2 Cyclic derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-06 US disclosed
EP-1620391-A4 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL MYERS SQUIBB CO (US) 2007-10-31 EP disclosed
EP-1720857-A1 DIHYDROPYRIDINONE DERIVATIVES Bayer HealthCare AG (DE) 2006-11-15 EP disclosed
EP-1620391-A2 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Bristol-Myers Squibb Company (US) 2006-02-01 EP disclosed
WO-2005080372-A1 DIHYDROPYRIDINONE DERIVATIVES BAYER HEALTHCARE AG (DE) 2005-09-01 WO disclosed
WO-2005080372-A1 DIHYDROPYRIDINONE DERIVATIVES BAYER HEALTHCARE AG (DE) 2005-09-01 WO disclosed
US-20040235836-A1 Cyclic derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY 2004-11-25 US disclosed
WO-2004098516-A2 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2004-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235836-A1 Cyclic derivatives as modulators of chemokine receptor activity CCL11, CCR1, CCL2 ALDH1A1 1095/4885HTT 4462/4885MEN1 2716/4885
US-20080108678-A1 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CCL11, CCL2, CCR1 ALDH1A1 1345/4885HTT 4443/4885MEN1 3068/4885
US-20080045541-A1 Dihydropyridinone Derivatives TNNI3, DHPS, TNNT2 ALDH1A1 721/4885HTT 4647/4885MEN1 4426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.